^
Association details:
| Biomarker: | PIK3CA H1047R |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas
Excerpt:
...Detroit562 cells harbour a H1047R mutation in the PI3K gene; Kyse30 cells harbour a Q61L mutation in the H-Ras gene… However, Detroi562 and Kyse30 cells were resistant to cetuximab, exhibiting an IC50 value ⩾500 μg ml−1 (Figure 1A). All the human squamous cell lines were highly sensitive to PKI-587, with an IC50 value ⩽100 nm (Figure 1B).
DOI:
10.1038/bjc.2014.241
